Zobrazeno 1 - 10
of 1 168
pro vyhledávání: '"Jilma P"'
Autor:
Jorda A, Eberl S, Nussbaumer-Pröll A, Sarhan M, Weber M, Tegrovsky LE, Wahrmann M, al Jalali V, Bergmann F, Pracher L, Leutzendorff A, Farlik M, Jilma B, Zeitlinger M
Publikováno v:
Journal of Inflammation Research, Vol Volume 17, Pp 4781-4790 (2024)
Anselm Jorda,1 Sabine Eberl,1 Alina Nussbaumer-Pröll,1 Maysa Sarhan,2 Maria Weber,1 Lara Elisabeth Tegrovsky,1 Markus Wahrmann,2 Valentin al Jalali,1 Felix Bergmann,1,3 Lena Pracher,1 Amelie Leutzendorff,1 Matthias Farlik,4 Bernd Jilma,1 Markus Zeit
Externí odkaz:
https://doaj.org/article/6e91a58f5cd4454dbd10594a6a73a318
Autor:
Maria Pilar Ruiz Seco, José Ramón Paño Pardo, Christian Schoergenhofer, Christiane Dings, Thorsten Lehr, Felix Herth, Andriy Krendyukov, Carola Straub, Martin Kappler, Bernd Jilma, Harald Fricke, Julian Pardo, Diego de Miguel, Meinolf Thiemann, Michael Bergmann, Henning Walczak, Thomas Hoeger
Publikováno v:
EClinicalMedicine, Vol 77, Iss , Pp 102879- (2024)
Summary: Background: The phase 2 ASUNCTIS study assessed the efficacy and safety of asunercept, a fully human CD95 (Fas) ligand-binding protein, in hospitalised patients with moderate-to-severe coronavirus disease (COVID-19) to assess the clinical be
Externí odkaz:
https://doaj.org/article/f34a85026187404385bbd167989aeaf9
Autor:
Anselm Jorda, Christian Hengstenberg, Irene M. Lang, Alexandra Kautzky-Willer, Jürgen Harreiter, Markus Zeitlinger, Bernd Jilma, Georg Gelbenegger
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract Background There is conflicting evidence whether prediabetes is associated with adverse clinical outcomes in patients with chronic coronary syndrome. We aimed to assess the effect of prediabetes in patients with chronic coronary syndrome on
Externí odkaz:
https://doaj.org/article/60ca539e3ee548b0929bec0d6d6fdf0c
Publikováno v:
Revista Científica de FAREM-Estelí, Iss 13 (2015)
Externí odkaz:
https://doaj.org/article/5a99ab64d9a7438b989199235a697f50
Autor:
Jilma Pereyra López
Publikováno v:
Revista Científica de FAREM-Estelí, Iss 13 (2015)
Externí odkaz:
https://doaj.org/article/2256cfe0b3ab4d3db58265cb0aae9c7a
Publikováno v:
Revista Científica de FAREM-Estelí, Iss 13 (2015)
Externí odkaz:
https://doaj.org/article/c58cd5f669694819ae3b3ec080978771
Publikováno v:
Revista Científica de FAREM-Estelí, Iss 13 (2015)
Externí odkaz:
https://doaj.org/article/f1a25e7329984c10ac9e072800ff2bfa
Autor:
Ulla Derhaschnig, Nina Buchtele, Margarete M. Steiner, Christa Drucker, Christa Firbas, Christian Schörgenhofer, Georg Gelbenegger, Franz König, Bernd Jilma, Katarina D. Kovacevic Miljevic
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 6, Pp 102518- (2024)
Background: Recombinant tissue plasminogen activator (rt-PA) is a thrombolytic agent and essential in emergency medical care. Given recent supply shortages, the availability of biosimilar products is an urgent medical need. However, biosimilarity tri
Externí odkaz:
https://doaj.org/article/320aceae17f847ab935a975f45d5f00f
Autor:
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M.I. Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Deepthi Jayawardene, Shruti Srivastava, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102733- (2024)
Summary: Background: Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia mediated by the classical complement pathway (CP). Sutimlimab selectively targets complement C1s inhibiting classical CP activation. In CADENZA Part A (26-week
Externí odkaz:
https://doaj.org/article/3d87b23487004a108e8a911cd7c2cb67
Autor:
Christian Schoergenhofer, Georg Gelbenegger, Dzenita Hasanacevic, Léa Schöner, Margarete M. Steiner, Christa Firbas, Nina Buchtele, Ulla Derhaschnig, Andreas Tanzmann, Nina Model, Julian Larcher-Senn, Manuel Drost, Martha M. Eibl, Andreas Roetzer, Bernd Jilma
Publikováno v:
EClinicalMedicine, Vol 67, Iss , Pp 102404- (2024)
Summary: Background: Toxic shock syndrome toxin-1 (TSST-1) is a superantigen produced by Staphylococcus aureus that causes the life-threatening toxic shock syndrome. The development of a safe and immunogenic vaccine against TSST-1 remains an unmet me
Externí odkaz:
https://doaj.org/article/c5ad4265a94d4108997a1f30384cf6b2